

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 27, 2003, 08:52:12 ; Search time 44 seconds

(without alignments)
626,884 Million cell updates/sec

Title: US-09-836-960-5

Perfect score: 1097
Sequence: 1 MYSAPSACRCLHFLLCF.....PFKTYTVTKRSRRIRPTHPA 207

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A.Geneseq_101002.*
1: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1097	100.0	207	19	AAW57413
2	1097	100.0	207	20	AAW57413
3	1097	100.0	207	20	AAW57413
4	1097	100.0	207	21	AAW57413
5	1097	100.0	207	21	AAW57413
6	1097	100.0	207	21	AAW57413
7	1097	100.0	207	22	AAW57413
8	1097	100.0	207	22	AAW57413
9	1097	100.0	207	22	AAW57413
10	1097	100.0	207	22	AAW57413

11	1097	100.0	207	23	AAE18823	Human FGF-18 prote
12	1081	98.5	207	21	AAW56818	Rat fibroblast gro
13	1081	98.5	207	21	AAW56819	Mouse fibroblast g
14	1081	98.5	207	22	AAW56845	Murine fibroblast
15	1081	98.5	207	22	AAE04537	Mouse fibroblast g
16	932	85.0	194	21	AAW44843	Human heart specif
17	835	76.1	160	20	AAW39630	Human fibroblast g
18	686	62.5	130	23	AAW1309	Human FGF18 core s
19	596	54.3	215	19	AAW53034	Fibroblast growth
20	591	53.9	215	16	AAW1650	AlfG #1. Homo sap
21	591	53.9	215	14	AAW80783	Fibroblast growth
22	591	53.9	215	16	AAW0815	FGF-8. Homo sapie
23	591	53.9	215	21	AAW92621	Human fibroblast g
24	591	53.9	215	21	AAW90417	FGF-8, SEQ ID NO:1
25	591	53.9	215	22	AAW09231	Mouse fibroblast g
26	591	53.9	215	22	AAW89932	Human FGF-8 protei
27	591	53.9	215	22	AAW47051	Heart muscle cell
28	591	53.9	215	22	AAW47051	hFGF-8 polypeptide
29	591	53.9	215	22	AAW50280	Human FGF-8 SEQ ID
30	586	53.4	215	19	AAW5718	Fibroblast growth
31	586	53.4	215	21	AAW32340	Human fibroblast g
32	574.5	52.4	204	22	AAW47050	hFGF-8 polypeptide
33	571	52.1	216	22	AAW50272	Human fibroblast g
34	571	52.1	220	23	AAW50272	Human fibroblast g
35	571	52.1	220	23	AAW50272	Human FGF-17 prote
36	569.5	51.9	244	22	AAW47053	hFGF-8 polypeptide
37	568	51.8	216	19	AAW70330	Fibroblast growth
38	567.5	51.7	205	20	AAW13348	Amino acid sequenc
39	567.5	51.7	205	20	AAW05279	FGF-8 homologue PR
40	567.5	51.7	205	21	AAW4392	Human PRO187 prote
41	567.5	51.7	205	21	AAW8567	Human PRO187 amino
42	567.5	51.7	205	22	AAW12308	Human PRO187 polyp
43	567.5	51.7	205	22	AAW68552	PRO187. Homo sapl
44	567.5	51.7	205	22	AAW1203	Amino acid sequenc
45	567.5	51.7	205	22	AAW80216	Human PRO187 prote

ALIGNMENTS

RESULT 1
AAW57413
ID AAW57413 standard; Protein: 207 AA.

AC AAW57413.
DT 24-SEP-1998 (first entry)

DE Amino acid sequence of fibroblast growth factor homologue zFGF-5.

XX Human: fibroblast growth factor homologue; zFGF-5; cardiac cell;
KW antagonist; antibody; heart failure; stroke; hypertension; cancer;
KW bone defects; arthritis; cardiac myocyte hyperplasia.

XX Homo sapiens.

XX PN WO9816644-A1.

XX PD 23-APR-1998.

XX PF 16-OCT-1997; 97WO-US18635.

XX PR 16-OCT-1996; 96US-0028646.

XX (ZYMO) ZYMOGENETICS INC.

XX PI Bukowski TR, Conklin DC, Delsher TA, Hansen B, Holderman SD;

XX PI Raymond FC, Sheppard PO;

XX WPI; 1998-251291/22.

XX N-PSDB; AAW29632.
New fibroblast growth factor homologue, zFGF-5 - used to develop

News Rules ?

PT products for treating e.g. heart failure, stroke, hypertension, bone
XX defects or cancers, arthritis, or wounds
PS Claim 14; Page 75; p 94pp: English.
XX
CC This is the amino acid sequence of the novel fibroblast growth factor
CC homologue zFGF-5, used in the method of the invention. The zFGF-5
CC polypeptides can be used (optionally ex vivo) for enhancing the
CC proliferation of cardiac tissue cells. The polypeptides, nucleic
CC acids, antagonists, and antibodies can also be used in the treatment
CC of disorders such as heart failure, stroke, hypertension, bone defects,
CC cancer, arthritis, or wounds. The products can also be used in the
CC study of cardiac myocyte hyperplasia and regeneration, to target
CC delivery of agents to the heart and for detection and diagnosis. The
CC recombinant cells can be used to produce the protein.
XX
SQ Sequence 207 AA;
Query Match 100.0%; Score 1097; DB 19; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MYSAPSACTCLCHFLLCFOVOVLVAEENVDRIRIHENOTRARDDVSRKOLRLVQLYSR 60
Db 1 MYSAPSACTCLCHFLLCFOVOVLVAEENVDRIRIHENOTRARDDVSRKOLRLVQLYSR 60
QY 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFFGSOVRIRKETEFLCMNRKGLVGRK 120
Db 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFFGSOVRIRKETEFLCMNRKGLVGRK 120
QY 121 DGSKECVFIEKYLENNYTLMSAKYSGWYVGTGKGRPKRKPTRENOODVHFMRKYPK 180
Db 121 DGSKECVFIEKYLENNYTLMSAKYSGWYVGTGKGRPKRKPTRENOODVHFMRKYPK 180
QY 181 GPELOKPFKYTTVTKRSRRIRPTHPA 207
Db 181 GPELOKPFKYTTVTKRSRRIRPTHPA 207
RESULT 2
AA39628
ID AAY39628 standard; Protein; 207 AA.
XX
AC AAY39628;
XX
DT 23-NOV-1999 (first entry)
XX
DE Human fibroblast growth factor 98 protein sequence.
XX
KW Fibroblast growth factor 98, FGF98; human: multipotent neural stem cell;
KW progenitor cell; peripheral neuropathy; amyotrophic lateral sclerosis;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease; dementia;
KW ischaemic stroke; brain injury; acute spinal cord injury; infection;
KW nervous system tumour; multiple sclerosis; epilepsy; metabolic disease;
KW peripheral nerve trauma; retinitis pigmentosa; macular degeneration;
KW retinal detachment; myocardial infarction; peripheral vascular disease;
KW renal artery disease; diagnosis; therapy.
XX
OS Homo sapiens.
XX
PN WO9946381-A2.
XX
PD 16-SEP-1999.
XX
PF 09-MAR-1999; 99WO-US05235.
XX
PR 09-MAR-1998; 98US-0077411.
PR 29-APR-1998; 98US-0083553.
PR 08-MAR-1999; 99US-0264851.
XX
XX (CHIR) CHIRON CORP.
XX
PI Cen H, Garcia PD, Grieshammer U, Kassam A, Lee PP, Pot D;

PI Gospodarowicz D, Martin K;
XX
DR WPI: 1999-551410/46.
DR N-PSDB; AA220593.
XX
PT New polynucleotide encoding a fibroblast growth factor, useful for
PT treating peripheral neuropathy, Alzheimer's disease, ischaemic stroke,
PT brain or spinal cord injury, nervous system tumours, multiple sclerosis
PT or epilepsy -
XX
PS Claim 5; Page 60; 60pp: English.
XX
XX This sequence is the human fibroblast growth factor 98 (FGF98) of
CC the invention. FGF98 can be used for the isolation, regeneration,
CC proliferation, and differentiation of mammalian multipotent neural stem
CC cells, progenitor cells and progeny. Primary central (CNS) and peripheral
CC nervous system (PNS) cells when treated with FGF98 proliferate, have at
CC least a limited self regeneration capacity, and can undergo lineage
CC restriction in response to the local environment. The FGF98 sequences can
CC be used for providing trophic support for cells in a patient. They be
CC used to treat e.g. peripheral neuropathy, amyotrophic lateral sclerosis,
CC Alzheimer's disease, Parkinson's disease, Huntington's disease, ischaemic
CC stroke, brain injury, acute spinal cord injury, nervous system tumours,
CC multiple sclerosis, infection, dementia, epilepsy, peripheral nerve
CC trauma or injury, exposure to neurotoxins, metabolic diseases, disorders
CC of insufficient blood cells, retinitis pigmentosa, age-related macular
CC degeneration, retinal detachment, myocardial ischaemia/infarction,
CC peripheral vascular disease, renal artery disease and wound healing.
CC Cells produced by treatment with FGF98 are also used to screen drugs and
CC growth factors, which may affect development, differentiation, survival
CC and/or function of CNS and PNS derived neurons and glia. FGF98 can also
CC be used for the production of large amounts of otherwise minor
CC populations of cells to be used for generation of cDNA libraries for the
CC isolation of rare molecules expressed in precursor cells or progeny;
CC cells produced by treatment may directly express growth factors or other
CC molecules.
XX
SQ Sequence 207 AA;
Query Match 100.0%; Score 1097; DB 20; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MYSAPSACTCLCHFLLCFOVOVLVAEENVDRIRIHENOTRARDDVSRKOLRLVQLYSR 60
Db 1 MYSAPSACTCLCHFLLCFOVOVLVAEENVDRIRIHENOTRARDDVSRKOLRLVQLYSR 60
QY 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFFGSOVRIRKETEFLCMNRKGLVGRK 120
Db 61 TSGKHIOVLGRIRISARGEDGDKYAQLLVETDFFGSOVRIRKETEFLCMNRKGLVGRK 120
QY 121 DGSKECVFIEKYLENNYTLMSAKYSGWYVGTGKGRPKRKPTRENOODVHFMRKYPK 180
Db 121 DGSKECVFIEKYLENNYTLMSAKYSGWYVGTGKGRPKRKPTRENOODVHFMRKYPK 180
QY 181 GPELOKPFKYTTVTKRSRRIRPTHPA 207
Db 181 GPELOKPFKYTTVTKRSRRIRPTHPA 207
RESULT 3
AA08590
ID AAY08590 standard; Protein; 207 AA.
XX
AC AAY08590;
XX
DT 05-AUG-1999 (first entry)
XX
DE Human FGF-18 protein fragment.
XX
KW PRO533; FGF-19; fibroblast growth factor; human: diagnosis; treatment;
KW tumour; neoplastic cell growth; cell proliferation; tumorigenesis; cancer;
KW autocrine signalling; Fgf-18.

Query Match	100.0%	Score 1097;	DB 20;	Length 207;
Best Local Similarity	100.0%	Pred. No. 9.3e-111;		
Matches 207;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0
QY 1	MYSPSACTGCGHFLFLCEYOVOVLAEEVNFRIHVENOTPARDVSRKOLRLYOLYSR	60		
DB 1	MTSPSPACTGCGHFLFLCEYOVOVLAEEVNFRIHVENOTPARDVSRKOLRLYOLYSR	60		
QY 61	TSGKHIOVLGRRISARGEDGDKYAQLLVTFDFGSGQVRKIKETEFYLCNNRKKGLVGP	120		
DB 61	TSGKHIOVLGRRISARGEDGDKYAQLLVTFDFGSGQVRKIKETEFYLCNNRKKGLVGP	120		
QY 121	DGTSKECVLETKVLENNYATALMSAKYSGMYVFTKKGRPRKGPRTRENQODVHFMRKRPK	180		
DB 121	DGTSKECVLETKVLENNYATALMSAKYSGMYVFTKKGRPRKGPRTRENQODVHFMRKRPK	180		
QY 181	GQPELOKPEKYYTVTKRSRIRPTHPA	207		
DB 181	GQPELOKPEKYYTVTKRSRIRPTHPA	207		

RESULT 4
AA87857
ID AA87857 standard; protein: 207 AA.
AC AA87857;
XX
XX 01-SEP-2000 (first entry)
XX
XX Human FGF-98 protein fragment.
XX

KW		FGF-98-fibroblast growth factor; cardiant; treatment; angiogenesis;
XV		coronary artery disease; myocardial infarction injury; human.
XX	Homo sapiens.	
OS		
PN	MO200021548-A2.	
XX		
PD	20-Apr-2000.	
XX		
PF	13-OCT-1999; 99WO-US22936.	
XX		
PR	13-OCT-1998; 98US-0104103.	
XX		
PA	(CHIR) CHIRON CORP.	
XX	(WHIT/) WHITEHOUSE M J.	
PI	Kavanaugh WM;	
XX		
DR	WPI: 2000-317840/27.	
PT		
PT	Novel unit dose comprising fibroblast growth factor, its angiogenically	
PT	active fragment or mutain for inducing cardiac angiogenesis, treating	
PT	coronary artery disease and reducing post myocardial infarction injury	
XX		
PS	Claim 1; Page 65-66; 67pp; English.	
XX		
CC	This invention describes a novel unit dose (I), of fibroblast growth	
CC	factor (FGF) comprising 0.008-6.1 mg of a mammalian FGF comprising	
CC	sequence of 140 (II) and (III)) 146 (IV) and (V)), 205 (VI), 266	
CC	(VII), 207 (VIII) and (XI)), 215 (IX), and 208 (X) amino acids (aa),	
CC	given in the specification, its angiogenically active fragment or	
CC	mutain. The product of the invention has angiogenic and cardiant	
CC	activity. (I) is used for treating a human patient for coronary artery	
CC	disease, and inducing angiogenesis in the human heart. (I) further	
CC	provides an adjunct for reducing post myocardial infarction injury in	
CC	humans. The unit dose provides the human patient with a rapid and	
CC	therapeutic cardiac angiogenesis sufficient to obviate surgical	
CC	intervention and results in an superior increase in the treated	
CC	patients's exercise tolerance time (ETT). It also provides a safe and	
CC	therapeutically efficacious treatment for the patients with coronary	
CC	artery disease that lasts at least 6 months before a further treatment	
CC	is needed. The method provides superior increase of 1.5-2 minutes in	
CC	the treated patient's (ETT), compared to an increase of 30 seconds for	
CC	current modes treatment. This sequence represents the human FGF-98	
CC	protein fragment described in the method of the invention.	
XX		
SQ	Sequence 207 AA:	
	Query Match 100.0%; Score 1097; DB 21; Length 207;	
	Best Local Similarity 100.0%; Pred. No. 9.3e-111;	
	Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
OY	1 MTSAPSACTCLCFLHLLLCFOYUOLVAEENVDRIHVENQTRARDYSKQLRLYOLYSR 60	
DB	1 MTSAPSACTCLCFLHLLLCFOYUOLVAEENVDRIHVENQTRARDYSKQLRLYOLYSR 60	
OY	61 TSGKHIOVLGRISARGEDGDKYLAVLLETPFGSOVRIKGKETEPFYLCMNRKGKLVGRP 120	
DB	61 TSGKHIOVLGRISARGEDGDKYLAVLLETPFGSOVRIKGKETEPFYLCMNRKGKLVGRP 120	
OY	121 DGTSECEVFIEKEVLNNNTALMSAKYSGWYGFTTKGGRPKRPKTRENOQDVHFMKRYRK 180	
DB	121 DGTSECEVFIEKEVLNNNTALMSAKYSGWYGFTTKGGRPKRPKTRENOQDVHFMKRYRK 180	
OY	181 GOPELOKPFKYTTVTKRSRIRPTHPA 207	
DB	181 GOPELOKPFKYTTVTKRSRIRPTHPA 207	
RESULT 5		
AAV44844		
ID	AAV44844 standard; Protein: 207 AA.	

```
XX AAY44844;
AC 18-MAY-2000 (first entry)
DT
XX
XX Human heart specific FGF-8b protein (confirmed sequence).
DE
XX
XX Human: heart specific fibroblast growth factor-8b; FGF-8b;
KM secreted protein; angiogenesis; anti-angiogenesis; cell differentiation;
KW diagnosis; prognosis; screening; treat; cancer; ischaemic heart disease;
XX vascular.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Peptide 1..27
FT /label= Signal_peptide
FT Protein 28..207
FT /label= Mature_FGF-8b
FT Region 1..181
FT /note= "shows 80% homology with various human growth
FT factors"
FT
XX
XX MO200005369-A2.
XX
XX 03-FEB-2000.
XX
XX 20-JUL-1999; 99MO-US12839.
XX
XX 20-JUL-1998; 98US-0093397.
XX 10-SEP-1998; 98US-0150684.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shinkets RA;
XX
XX WPI; 2000-182696/16.
XX N-PSDB; AA250351.
XX
XX Novel angiogenesis and anti-angiogenesis secreted proteins used to
XX control angiogenesis
XX
XX Claim 28; Fig 3B; 32pp; English.
XX
XX The present sequence is a confirmed sequence of
XX heart specific fibroblast growth factor-8b (FGF-8b), an angiogenesis/
XX anti-angiogenesis secreted protein from human heart library.
XX The protein exhibits angiogenic
XX (either inducing or inhibiting) or cell differentiation activity.
XX The present sequence can be used for diagnosis, prognosis, screening
XX and treating diseases and disorders associated with aberrant levels of
XX the secreted protein. The protein can be used to control angiogenesis
XX e.g. in cancers, ischaemic heart and vascular diseases.
XX
XX
XX Sequence 207 AA:
SQ
Query Match 100.0%; Score 1097; DB 21; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
DB 181 GPELOKPFKYYTWTVKRSRIRPTHPA 207
|||||
RESULT 6
AA56817
ID AAY56817 standard; Protein; 207 AA.
XX
XX AAY56817;
AC
XX
XX 31-MAR-2000 (first entry)
DT
XX
XX Human fibroblast growth factor (FGF).
DE
XX
XX Fibroblast growth factor; FGF; tissue formation;
XX Lung tissue interference; human.
XX
XX Homo sapiens.
XX
XX JP11332570-A.
XX
XX 07-DEC-1999.
XX
XX 27-MAY-1998; 98JP-0145478.
XX
XX 27-MAY-1998; 98JP-0145478.
XX
XX (SHIO ) SHIONOGI & CO LTD.
XX
XX WPI; 2000-091354/08.
XX N-PSDB; AA246767.
XX
XX A new fibroblast growth factor and a gene coding it - useful for
XX prevention, treatment and diagnosis of tissue formation interference or
XX treatment of lung tissue interference
XX
XX Claim 1; Page 7-8; 16pp; Japanese.
XX
XX The invention provides fibroblast growth factor (FGF) proteins from
XX human, rat and mouse. FGF is useful for prevention, treatment and
XX diagnosis of tissue formation interference or treatment of lung tissue
XX interference. The present sequence represents a human FGF.
XX
XX
XX Sequence 207 AA:
SQ
Query Match 100.0%; Score 1097; DB 21; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

XX DE Human fibroblast growth factor (FGF)-18.
XX XX
KM Fibroblast growth factor; FGF; FGF-like polypeptide; mitogenic;
KM fat deposition; vulnery; antitumor; dermatological; anorectic;
KM antidiabetic; antiinflammatory; cytostatic; hepatic; virucide;
KM neuroprotectant; pulmonary; gene therapy; vaccine; human.
XX OS
XX Homo sapiens.
XX PN WO200172957-A2.
XX PD
XX PD 04-OCT-2001.
XX PF 02-APR-2001; 2001WO-1B00664.
XX PR 31-MAR-2000; 2000US-0540118.
XX PA (ITOH/) ITOH N.
XX PI Itoh N;
XX DR WPI; 2001-611623/70.
XX PT New human nucleic acid encoding fibroblast growth factor-like peptide,
PT useful for treatment and diagnosis of e.g. wounds and inflammatory
PT bowel disease -
XX PS
XX PS Disclosure; Fig 3; 172pp; English.
XX XX
CC The invention provides human nucleic acids encoding fibroblast growth
CC factor (FGF)-like peptide. The FGF-like polypeptides can be expressed by
CC standard recombinant methodology and are mitogenic for a wide range of
CC cells, inducing differentiation and proliferation, and inhibiting
CC deposition of fat. The FGF-like polypeptides, polynucleotides and
CC specific antibodies and modulators are useful for treating a very wide
CC range of diseases and conditions, e.g. wounds, ulcers, skin aging,
CC obesity, diabetes, alopecia, inflammatory bowel disease, emphysema, viral
CC hepatitis, multiple sclerosis, respiratory distress syndrome, tumors of
CC the eye, etc., also for maintaining organs before transplant and
CC supporting culture of primary cells and tissues. Sequences AAG5647-67
CC represent amino acid sequences of some members of the FGF family.
XX SQ
XX Sequence 207 AA;
Query Match 100.0%; Score 1097; DB 22; Length 207;
Best Local Similarity 100.0%; Pred. No. 9,3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MYSAPSACTGCTCLHFLLCFOVOVLVAEENVDFRIHVENOTRARDVSRKQLRLYQLYSR 60
DB 1 MYSAPSACTGCTCLHFLLCFOVOVLVAEENVDFRIHVENOTRARDVSRKQLRLYQLYSR 60
QY 61 TSGKHIOVLGRISARGEDGDKYAQLLVETDFTGSGQVRIRKETEFTYLCNNRKGKLVGKP 120
DB 61 TSGKHIOVLGRISARGEDGDKYAQLLVETDFTGSGQVRIRKETEFTYLCNNRKGKLVGKP 120
QY 121 DGTSGKECVFTEKYLENNYTAALMSAKYSGWYVGFTRKGRPRKGPRTRENODVHFMRKRYPK 180
DB 121 DGTSGKECVFTEKYLENNYTAALMSAKYSGWYVGFTRKGRPRKGPRTRENODVHFMRKRYPK 180
QY 181 GPELOKPFKYTVTKRSRIRPTHPA 207
DB 181 GPELOKPFKYTVTKRSRIRPTHPA 207

RESULT 8
AAB85827
ID AAB85827 standard; Protein; 207 AA.
XX AC AAB85827;
XX DT 29-OCT-2001 (first entry)

XX DE Human fibroblast growth factor (FGF)-17.
XX XX
KM Fibroblast growth factor; FGF; FGF-23; osteopathic; vulnery; ADHR;
KM hepatocytic; autosomal dominant hypophosphatemic rickets; human;
KM angiogenesis; gene-therapy; liver disorder; antisense-therapy.
XX OS
XX Homo sapiens.
XX PN WO200161007-A2.
XX PD
XX PD 23-AUG-2001.
XX PF 15-FEB-2001; 2001WO-US04778.
XX PR 15-FEB-2000; 2000US-0182442.
XX PR 20-APR-2000; 2000US-0198903.
XX PR 15-FEB-2001; 2001US-0748581.
XX PA (AMGE-) AMGEN INC.
XX PI Luethy R, Yang R, Suggs S, Sarosi D;
XX DR WPI; 2001-514774/56.
XX PT An isolated nucleic acid molecule encoding a fibroblast growth factor
PT 23 useful for treating autosomal dominant hypophosphatemic rickets -
XX PS
XX PS Example 1; Fig 2A-G; 158pp; English.
XX XX
CC The invention provides a human fibroblast growth factor (FGF)-23
CC polypeptide. The encoding DNA insert is contained in ATCC Deposit No.
CC PTA-1617. FGF-23 can be expressed by standard recombinant methodology.
CC The FGF-23 polypeptides, polynucleotides, modulators and antibodies are
CC useful for treating, preventing, or ameliorating an FGF-23 polypeptide-
CC related disease, condition or disorder especially autosomal dominant
CC hypophosphatemic rickets (ADHR). They are also useful for diagnosing a
CC pathological condition and for stimulating angiogenesis, promoting wound
CC healing and treating disorders of the liver. Sequences AAB85812-23
CC represent human FGF protein sequences used for comparison studies with
CC FGF-23.
XX SQ
XX Sequence 207 AA;
Query Match 100.0%; Score 1097; DB 22; Length 207;
Best Local Similarity 100.0%; Pred. No. 9,3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MYSAPSACTGCTCLHFLLCFOVOVLVAEENVDFRIHVENOTRARDVSRKQLRLYQLYSR 60
DB 1 MYSAPSACTGCTCLHFLLCFOVOVLVAEENVDFRIHVENOTRARDVSRKQLRLYQLYSR 60
QY 61 TSGKHIOVLGRISARGEDGDKYAQLLVETDFTGSGQVRIRKETEFTYLCNNRKGKLVGKP 120
DB 61 TSGKHIOVLGRISARGEDGDKYAQLLVETDFTGSGQVRIRKETEFTYLCNNRKGKLVGKP 120
QY 121 DGTSGKECVFTEKYLENNYTAALMSAKYSGWYVGFTRKGRPRKGPRTRENODVHFMRKRYPK 180
DB 121 DGTSGKECVFTEKYLENNYTAALMSAKYSGWYVGFTRKGRPRKGPRTRENODVHFMRKRYPK 180
QY 181 GPELOKPFKYTVTKRSRIRPTHPA 207
DB 181 GPELOKPFKYTVTKRSRIRPTHPA 207

RESULT 9
AAE04536
ID AAE04536 standard; Protein; 207 AA.
XX AC AAE04536;
XX DT 10-SEP-2001 (first entry)

```
DE Human fibroblast growth factor (zFGF5).
XX
KW Human; fibroblast growth factor-18; FGF-18; zFGF5; FGF receptor-2;
KW FGF receptor-3; cytoxin; cell proliferation inhibitor; tumour;
KW multiple myeloma; bladder carcinoma; cervix carcinoma; cytostatic;
KW thyroid carcinoma; osteosarcoma.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..27
FT /label= Signal_peptide
FT 28..207
FT Protein /note= "Human mature fibroblast growth factor (zFGF5)"
XX
XX WO200139788-A2.
XX
XX 07-JUN-2001.
XX
XX 28-NOV-2000; 2000MO-US32380.
XX
XX 02-DEC-1999; 99US-0452977.
XX
XX (ZYMO ) ZYMOGENETICS INC.
XX
XX West JW;
XX
XX WPI; 2001-417789/44.
XX
XX N-PSDB; AAD07795.
XX
XX Novel fibroblast growth factor targeting composition useful for
XX inhibiting the proliferation of cells expressing FGF receptor 3 or FGF
XX receptor 2
XX
XX Claim 3; Page 59; 62pp; English.
XX
XX The present invention relates to methods for targeting cells that
XX express fibroblast growth receptor-3 or -2. Fibroblast growth
XX factor-18 (FGF-18) binds with FGF receptor-2 and -3. A targeting
XX composition comprising FGF-18 component and cytoxin, is useful for
XX inhibiting the proliferation of cells that express FGF receptor-3 or
XX -2, in a subject having tumour cells such as multiple myeloma cells,
XX bladder carcinoma cells, cervix carcinoma cells, thyroid carcinoma
XX cells, osteosarcoma cells and intimal smooth muscle cells. The present
XX sequence is human zFGF5 protein.
XX
XX Sequence 207 AA;
XX
XX Query Match 100.0%; Score 1097; DB 22; Length 207;
XX Best Local Similarity 100.0%; Pred. No. 9.3e-111;
XX Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MYSAPSACTCLCLHFLILCFQOVVLAENVDFRIHVENOTRARDVSRKQLRLYQLYSR 60
XX 1 MYSAPSACTCLCLHFLILCFQOVVLAENVDFRIHVENOTRARDVSRKQLRLYQLYSR 60
XX
XX 61 TSGKHIOVLGRRIISARGEDGDKYAQLLVETDFGSGVRIKGETEFYLCMNRKGLVGR 120
XX 61 TSGKHIOVLGRRIISARGEDGDKYAQLLVETDFGSGVRIKGETEFYLCMNRKGLVGR 120
XX
XX 61 TSGKHIOVLGRRIISARGEDGDKYAQLLVETDFGSGVRIKGETEFYLCMNRKGLVGR 120
XX 61 TSGKHIOVLGRRIISARGEDGDKYAQLLVETDFGSGVRIKGETEFYLCMNRKGLVGR 120
XX
XX 121 DQTSKRCVFIEKVLNNNTALMSAKYSGWYGFTRKGRPRKPKTRNOQDVHFMRKRPK 180
XX 121 DQTSKRCVFIEKVLNNNTALMSAKYSGWYGFTRKGRPRKPKTRNOQDVHFMRKRPK 180
XX
XX 121 DQTSKRCVFIEKVLNNNTALMSAKYSGWYGFTRKGRPRKPKTRNOQDVHFMRKRPK 180
XX 121 DQTSKRCVFIEKVLNNNTALMSAKYSGWYGFTRKGRPRKPKTRNOQDVHFMRKRPK 180
XX
XX 181 GPELOKPKKYTTVTKRSRIRPTHPA 207
XX 181 GPELOKPKKYTTVTKRSRIRPTHPA 207
XX
XX 181 GPELOKPKKYTTVTKRSRIRPTHPA 207
XX 181 GPELOKPKKYTTVTKRSRIRPTHPA 207
XX
XX RESULT 10
XX AAU01240
XX AAU01240 standard; Protein; 207 AA.
XX
```

```
AC AAU01240;
XX
XX 16-JUL-2001 (first entry)
XX
XX Human fibroblast growth factor homologue, zFGF-5.
XX
XX Human; fibroblast growth factor homologue; zFGF-5; plasmid construction;
XX homologous recombination.
XX
XX Homo sapiens.
XX
XX OS Homo sapiens.
XX
XX FH Key Location/Qualifiers
XX FT Peptide 1..26
XX FT /label= Signal_peptide
XX FT 27..207
XX FT Protein /label= Mature_zFGF-5
XX
XX US6207442-B1.
XX
XX 27-MAR-2001.
XX
XX 15-OCT-1998; 98US-0173043.
XX
XX 16-OCT-1997; 97US-0062061.
XX
XX (ZYMO ) ZYMOGENETICS INC.
XX
XX Raymond CK;
XX
XX WPI; 2001-256851/26.
XX
XX N-PSDB; AAS00951.
XX
XX Preparing a double-stranded, circular DNA molecule, involves homologous
XX recombination of one or more donor DNA fragments encoding the protein
XX of interest, with an acceptor plasmid and DNA linkers in host cell
XX
XX Example 5; Columns 27-30; 23pp; English.
XX
XX The sequence is a Human fibroblast growth factor homologue, zFGF-5,
XX used to demonstrate the method of the invention. The method of the
XX invention comprises preparing a double-stranded, circular DNA molecule,
XX comprising combining donor DNA fragments encoding the protein of interest
XX with an acceptor plasmid, and two DNA linkers in a Saccharomyces
XX cerevisiae host cell. The encoding DNA is linked to the acceptor plasmid
XX by homologous recombination of with the linkers and acceptor plasmid to
XX form the closed, circular plasmid. The obtained plasmid is useful for
XX transforming host cells and producing proteins of interest. The method
XX allows for production of a standardised plasmid into which a variety of
XX DNA sequences can be readily inserted and subsequently expressed.
XX
XX Sequence 207 AA;
XX
XX Query Match 100.0%; Score 1097; DB 22; Length 207;
XX Best Local Similarity 100.0%; Pred. No. 9.3e-111;
XX Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MYSAPSACTCLCLHFLILCFQOVVLAENVDFRIHVENOTRARDVSRKQLRLYQLYSR 60
XX 1 MYSAPSACTCLCLHFLILCFQOVVLAENVDFRIHVENOTRARDVSRKQLRLYQLYSR 60
XX
XX 61 TSGKHIOVLGRRIISARGEDGDKYAQLLVETDFGSGVRIKGETEFYLCMNRKGLVGR 120
XX 61 TSGKHIOVLGRRIISARGEDGDKYAQLLVETDFGSGVRIKGETEFYLCMNRKGLVGR 120
XX
XX 61 TSGKHIOVLGRRIISARGEDGDKYAQLLVETDFGSGVRIKGETEFYLCMNRKGLVGR 120
XX 61 TSGKHIOVLGRRIISARGEDGDKYAQLLVETDFGSGVRIKGETEFYLCMNRKGLVGR 120
XX
XX 121 DQTSKRCVFIEKVLNNNTALMSAKYSGWYGFTRKGRPRKPKTRNOQDVHFMRKRPK 180
XX 121 DQTSKRCVFIEKVLNNNTALMSAKYSGWYGFTRKGRPRKPKTRNOQDVHFMRKRPK 180
XX
XX 121 DQTSKRCVFIEKVLNNNTALMSAKYSGWYGFTRKGRPRKPKTRNOQDVHFMRKRPK 180
XX 121 DQTSKRCVFIEKVLNNNTALMSAKYSGWYGFTRKGRPRKPKTRNOQDVHFMRKRPK 180
XX
XX 181 GPELOKPKKYTTVTKRSRIRPTHPA 207
XX 181 GPELOKPKKYTTVTKRSRIRPTHPA 207
XX
XX 181 GPELOKPKKYTTVTKRSRIRPTHPA 207
XX 181 GPELOKPKKYTTVTKRSRIRPTHPA 207
XX
```

RESULT 11
AAE18823
ID AAE18823 standard; Protein; 207 AA.
XX
AC AAE18823;
XX
DT 17-MAY-2002 (first entry)
XX
DE Human FGF-18 protein.
XX
KW Fibroblast growth factor; FGF-like protein; wound healing; bullous;
KW epidermolysis; erosive gastritis; inflammatory bowel disease; ulcer;
KW oesophagitis; Crohn's disease; hyaline membrane disease; emphysema;
KW pulmonary fibrosis; hepatic cirrhosis; liver failure; angiogenesis;
KW multiple sclerosis; neurodegenerative disease; lung abnormality;
KW viral hepatitis; respiratory distress syndrome; tumour; skin aging;
KW gene therapy; vaccine; human.
XX
OS Homo sapiens.
XX
PN US2002001825-A1.
XX
PD 03-JAN-2002.
XX
PF 02-APR-2001; 2001US-0822485.
XX
PR 31-MAR-2000; 2000US-0540118.
XX
PA (ITOH/) ITOH N.
XX
PI Itoh N;
XX
DR WPI; 2002-187704/24.
XX
PT Novel fibroblast growth factor-like polypeptide useful for treating,
PT ameliorating and/or preventing dermal wounds, gastric ulcer, Crohn's
PT disease and pulmonary inflammation
XX
PS Disclosure; Fig 3; 63pp; English.
XX
CC The invention relates to fibroblast growth factor (FGF)-like
CC polypeptides and nucleic acid molecules encoding such polypeptides.
CC Sequences of the invention are useful for treating, preventing or
CC ameliorating a medical condition. They are useful for treating dermal
CC wounds, epidermolysis, bullous, male pattern alopecia, gastric ulcer,
CC duodenal ulcer, erosive gastritis, oesophagitis, oesophageal reflux
CC disease, inflammatory bowel disease, Crohn's disease, radiation- or
CC chemotherapy-induced gut toxicity, hyaline membrane disease, necrosis
CC of the respiratory epithelium, emphysema, pulmonary inflammation,
CC pulmonary fibrosis, hepatic cirrhosis, toxic insults to the liver,
CC fulminant liver failure, viral hepatitis, mucositis, multiple sclerosis
CC and other neurodegenerative diseases, infantile respiratory distress
CC syndrome, bronchopulmonary dysplasia, acute respiratory distress
CC syndrome or other lung abnormalities, tumours of the eye or the other
CC tissues and organs. FGF-like polypeptides are useful stimulating
CC angiogenesis, promoting wound healing, modulating differentiation of
CC neuronal cells, adipocytes and skeletal muscle cells, preventing or
CC ameliorate skin aging, preventing hair loss, stimulating the growth
CC and differentiation of haematopoietic cells and bone marrow cells and
CC maintaining organs before transplantation and for supporting cultures
CC of primary cells and tissues. Sequences of the invention are also
CC used in gene therapy and as vaccines. The present sequence is human
CC FGF-18 protein which is a member of the FGF family.
XX
SQ Sequence 207 AA:
XX
Query Match 100.0%; Score 1097; DB 23; Length 207;
Best local Similarity 100.0%; Pred. No. 9.3e-111;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX
QY 61 TSGKHIOVLGRRISARGEDGDKYAQLLVETDFESGVRIRKETEFLCMNRKGLVGP 120
DB 61 TSGKHIOVLGRRISARGEDGDKYAQLLVETDFESGVRIRKETEFLCMNRKGLVGP 120
QY 121 DGTSEKCEVFTEKYLENNYTTALMSAKYSGWYVGFTRKGRPRKGPRTRENODVHMKRYPK 180
DB 121 DGTSEKCEVFTEKYLENNYTTALMSAKYSGWYVGFTRKGRPRKGPRTRENODVHMKRYPK 180
QY 181 GPELQKPFKYYTIVTKRSRRIRPTHPA 207
DB 181 GPELQKPFKYYTIVTKRSRRIRPTHPA 207
XX
RESULT 12
AAV56818
ID AAV56818 standard; Protein; 207 AA.
XX
AC AAV56818;
XX
DT 31-MAR-2000 (first entry)
XX
DE Rat fibroblast growth factor (FGF).
XX
KW Fibroblast growth factor; FGF; tissue formation;
KW lung tissue interference; rat.
XX
OS Rattus sp.
XX
PN JP1332570-A.
XX
PD 07-DEC-1999.
XX
PF 27-MAY-1998; 98JP-0145478.
XX
PR 27-MAY-1998; 98JP-0145478.
XX
PA (SHIO) SHIONOGI & CO LTD.
XX
DR WPI; 2000-091354/08.
DR N-PSDB; AA426768.
XX
PT A new fibroblast growth factor and a gene coding it - useful for
PT prevention, treatment and diagnosis of tissue formation interference or
PT treatment of lung tissue interference
XX
XX Claim 1; Page 8-9; 16pp; Japanese.
XX
CC The invention provides fibroblast growth factor (FGF) proteins from
CC human, rat and mouse. FGF is useful for prevention, treatment and
CC diagnosis of tissue formation interference or treatment of lung tissue
CC interference. The present sequence represents a rat FGF.
XX
SQ Sequence 207 AA:
XX
Query Match 98.5%; Score 1081; DB 21; Length 207;
Best local Similarity 99.0%; Pred. No. 5.1e-109;
Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 181 GQTELOKPKYTTVTKRSRRIRPTHP 206

RESULT 13
AAV56819
ID AAV56819 standard; Protein: 207 AA.
XX
AC AAV56819;
XX
DT 31-MAR-2000 (first entry)
XX
DE Mouse fibroblast growth factor (FGF).
XX
KW Fibroblast growth factor; FGF; tissue formation;
KM lung tissue interference; mouse.
XX
OS Mus sp.
XX JPI1332570-A.
XX
PN 07-DEC-1999.
XX
PD 27-MAY-1998; 960P-0145478.
XX
PF 27-MAY-1998; 960P-0145478.
XX
PR 27-MAY-1998; 960P-0145478.
XX
PA (SHIO) SHIONOGI & CO LTD.
XX
DR WPI: 2000-091354/08.
DR N-PSDB: AA246769.
XX
XX
XX A new fibroblast growth factor and a gene coding it - useful for
PT prevention, treatment and diagnosis of tissue formation interference or
PT treatment of lung tissue interference
XX
PS Claim 1; Page 9-10; 16pp: Japanese.
XX
XX The invention provides fibroblast growth factor (FGF) proteins from
CC human, rat and mouse. FGF is useful for prevention, treatment and
CC diagnosis of tissue formation interference or treatment of lung tissue
CC interference. The present sequence represents a mouse FGF.
XX
SQ Sequence 207 AA:

Query Match 98.5%; Score 1081; DB 21; Length 207;
Best Local Similarity 99.0%; Pred. No. 5.1e-109;
Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MYSAPSACTCLCLHFLILLCFOYQVLAENVDRIHVENQTRARDVSRKQLRLYQLYSR 60
DB 1 MYSAPSACTCLCLHFLILLCFOYQVLAENVDRIHVENQTRARDVSRKQLRLYQLYSR 60
QY 61 TSGKHIQVGRRIISARGECDKYAQLLVETDFGSOVRIKGKETEFYLCMNRKGLVGR 120
DB 61 TSGKHIQVGRRIISARGECDKYAQLLVETDFGSOVRIKGKETEFYLCMNRKGLVGR 120
QY 121 DGTSEKCVIEFVLENNYATLMSAKYSGWYVGTGKGRPKRKPRTRENQDVHFMKRYRK 180
DB 121 DGTSEKCVIEFVLENNYATLMSAKYSGWYVGTGKGRPKRKPRTRENQDVHFMKRYRK 180
QY 181 GQPELOKPKYTTVTKRSRRIRPTHP 206
DB 181 GQPELOKPKYTTVTKRSRRIRPTHP 206

RESULT 14
AAB85845
ID AAB85845 standard; Protein: 207 AA.
XX
AC AAB85845;
XX
DT 29-OCT-2001 (first entry)
XX

DE Murine fibroblast growth factor (FGF)-17.
XX
XX Fibroblast growth factor; FGF; FGF-23; osteopathic; vulnary; ADHR;
KM hepatotropic; autosomal dominant hypophosphatemic rickets; mouse;
KM angiogenesis; gene-therapy; liver disorder; antisense-therapy.
XX
OS Mus musculus.
XX WO200161007-A2.
XX
XX 23-AUG-2001.
XX
PD 15-FEB-2001; 2001WO-US04778.
XX
PF 15-FEB-2001; 2000US-0182442.
XX
PR 20-APR-2000; 2000US-0198903.
XX
PR 15-FEB-2001; 2001US-0748581.
XX
PA (AMGE-) AMGEN INC.
XX
XX Luethy R, Yang R, Sugas S, Sarosi D;
XX WPI: 2001-514774/56.
XX
DR An isolated nucleic acid molecule encoding a fibroblast growth factor
PT 23 useful for treating autosomal dominant hypophosphatemic rickets -
XX
XX Example 1; Fig 2A-G; 158pp; English.
XX
XX The invention provides a human fibroblast growth factor (FGF)-23
CC polypeptide. The encoding DNA insert is contained in ATCC Deposit No.
CC PTA-1617. FGF-23 can be expressed by standard recombinant methodology.
CC The FGF-23 polypeptides, polynucleotides, modulators and antibodies are
CC useful for treating, preventing, or ameliorating an FGF-23 polypeptide-
CC related disease, condition or disorder especially autosomal dominant
CC hypophosphatemic rickets (ADHR). They are also useful for diagnosing a
CC pathological condition and for stimulating angiogenesis, promoting wound
CC healing and treating disorders of the liver. Sequences AAB85830-45
CC represent murine FGF protein sequences used for comparison studies with
CC human FGF-23.
XX
SQ Sequence 207 AA:

Query Match 98.5%; Score 1081; DB 22; Length 207;
Best Local Similarity 99.0%; Pred. No. 5.1e-109;
Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MYSAPSACTCLCLHFLILLCFOYQVLAENVDRIHVENQTRARDVSRKQLRLYQLYSR 60
DB 1 MYSAPSACTCLCLHFLILLCFOYQVLAENVDRIHVENQTRARDVSRKQLRLYQLYSR 60
QY 61 TSGKHIQVGRRIISARGECDKYAQLLVETDFGSOVRIKGKETEFYLCMNRKGLVGR 120
DB 61 TSGKHIQVGRRIISARGECDKYAQLLVETDFGSOVRIKGKETEFYLCMNRKGLVGR 120
QY 121 DGTSEKCVIEFVLENNYATLMSAKYSGWYVGTGKGRPKRKPRTRENQDVHFMKRYRK 180
DB 121 DGTSEKCVIEFVLENNYATLMSAKYSGWYVGTGKGRPKRKPRTRENQDVHFMKRYRK 180
QY 181 GQPELOKPKYTTVTKRSRRIRPTHP 206
DB 181 GQPELOKPKYTTVTKRSRRIRPTHP 206

RESULT 15
AAE04537
ID AAE04537 standard; Protein: 207 AA.
XX
AC AAE04537;
XX
DT 10-SEP-2001 (first entry)
XX
DE Mouse fibroblast growth factor (zFGF5).

XX Mouse; fibroblast growth factor-18; FGF-18; zFGF5; FGF receptor-2;
KW FGF receptor-3; cytotoxin; cell proliferation inhibitor; tumour;
KW multiple myeloma; bladder carcinoma; cervix carcinoma; cytostatic;
KW thyroid carcinoma; osteosarcoma.
XX
OS Mus musculus.
PN WO200139788-A2.
XX
XX 07-JUN-2001.
XX
XX 28-NOV-2000; 2000WO-US32380.
XX
XX 02-DEC-1999; 99US-0452977.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX West JW;
XX
XX WPI; 2001-417789/44.
XX
XX N-PSDB; AAD07796.
XX
XX Novel fibroblast growth factor targeting composition useful for
PT inhibiting the proliferation of cells expressing FGF receptor 3 or FGF
PT receptor 2
XX
XX Claim 4; Page 61-62; 62pp; English.
XX
XX The present invention relates to methods for targeting cells that
CC express fibroblast growth receptor-3 or -2. Fibroblast growth
CC factor-18 (FGF-18) binds with FGF receptor-2 and -3. A targeting
CC composition comprising FGF-18 component and cytotoxin, is useful for
CC inhibiting the proliferation of cells that express FGF receptor-3 or
CC -2, in a subject having tumour cells such as multiple myeloma cells,
CC bladder carcinoma cells, cervix carcinoma cells, thyroid carcinoma
CC cells, osteosarcoma cells and intimal smooth muscle cells. The present
CC sequence is mouse zFGF5 protein.
XX
SQ Sequence 207 AA;

Query Match 98.5%; Score 1081; DB 22; Length 207;
Best local Similarity 99.0%; Pred. No. 5,1e-109;
Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 MYSAPSACTGCLHFLILCFQVQVLAENVDFRIHVENOTRARDDVSRQRLYLQLYSR 60
DB 1 MYSAPSACTGCLHFLILCFQVQVLAENVDFRIHVENOTRARDDVSRQRLYLQLYSR 60
QY 61 TSGKHIOVLAGRISARGEDDGYAQLLVERDTGSOYRIKGETEFLCMNRKGLVGP 120
DB 61 TSGKHIOVLAGRISARGEDDGYAQLLVERDTGSOYRIKGETEFLCMNRKGLVGP 120
QY 121 DGTSGKECVFTEKVLNNYTLMSAKYSGWTVGFTKGRPKRGPXTRENODVHFMKRYPK 180
DB 121 DGTSGKECVFTEKVLNNYTLMSAKYSGWTVGFTKGRPKRGPXTRENODVHFMKRYPK 180
QY 181 GQPELOKPFKYTTVTKRSRIRPTHP 206
DB 181 GQPELOKPFKYTTVTKRSRIRPTHP 206

Search completed: April 27, 2003, 15:03:24
Job time : 46 secs

THIS PAGE BLANK (USPTO)